Neuroprotection by rasagiline in thiamine deficient rats

Brain Research

Volumn 1256, Issue , 2009, Pages 138-148

  Eliash, Sarah ^a   Dror, Vered ^a   Cohen, Sasson ^a   Rehavi, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

MAO B inhibitors; Neuroprotection; Pyrithiamine; Rasagiline; Selegiline; Thiamine deficiency (TD)

Indexed keywords

PYRITHIAMINE; RASAGILINE; SELEGILINE; THIAMINE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HISTOPATHOLOGY; INFERIOR COLLICULUS; MALE; MAZE TEST; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; THALAMUS; THIAMINE DEFICIENCY;

AGING; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; INDANS; KAPLAN-MEIERS ESTIMATE; MALE; MAZE LEARNING; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; THIAMINE DEFICIENCY;

ANIMALIA; RATTUS;

EID: 59649105230     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.11.097     Document Type: Article

References (77)

1. Abu-Raya S., Blaugrund E., Trembovler V., Shilderman-Bloch E., Shohami E., and Lazarovici P. Rasagiline, a monamine oxidase-B inhibitor protects NGF-differentiated PC-12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58 (1999) 456-463
2. Abu-Raya S., Tabakman R., and Blaugrund E. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol. 434 (2002) 109-116
3. Aggleton J.P., and Brown M.W. Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav. Brain Sci. 22 (1999) 425-489
4. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M.B., Tsujimoto Y., and Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82 (2002) 913-923
5. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M.B., and Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326 (2002) 105-108
6. Bar Am O., Amit T., and Youdim M.B.H. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355 (2004) 169-172
7. Bar-Am O., Weinreb O., Amit T., and Youdim M.B. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19 (2005) 1899-1901
8. Bar Am O., Amit T., and Youdim M.B.H. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 103 (2007) 500-508
9. Bubber P., Ke Z.J., and Gibson G.E. Tricarboxylic acid cycle enzymes following thiamine deficiency. Neurochem. Int. 45 (2004) 1012-1028
10. Butterworth R.F., Giguère J.F., and Besnard A.M. Activities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy. 2. Alpha-ketoglutarate dehydrogenase. Neurochem. Res. 11 (1986) 567-577
11. Carvalho F.M., Pereira S.R.C., Pires R.G.W., Ferraz V.P., Romano-Silva M.A., Oliveira-Silva I.F., and Ribeiro A.M. Thiamine deficiency decreases glutamate uptake in the prefrontal cortex and impairs spatial memory performance in a water maze test. Pharmacol. Biochem. Behav. 83 (2006) 481-489
12. Chen J.J., and Swope D.M. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 45 (2005) 878-894
13. Chen J.J., Swope D.M., and Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin. Ther. 9 (2007) 1825-1849
14. Eliash S., Speiser Z., and Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J. Neural Transm. 108 (2001) 909-923
15. Eliash S., Shteter N., and Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J. Neural Transm. 112 (2005) 991-1003
16. Fernandez H.H., and Chen J.J. Monoamine oxidase inhibitors: current and emerging agents for Parkinson's disease. Clin. Neuropharmacol. 30 (2007) 150-168
17. Finberg J.P., Lamensdorf I., Weinstock M., Schwartz M., and Youdim M.B. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv. Neurol. 80 (1999) 495-599
18. Gibson G.E., and Zhang H. Interactions of oxidative stress with thiamine homeostasis promote neurodegeneration. Neurochem. Int. 40 (2002) 493-504
19. Gibson G.E., Ksiezak-Reding H., Sheu K.F., Mykytyn V., and Blass J.P. Correlation of enzymatic, metabolic, and behavioral deficits in thiamin deficiency and its reversal. Neurochem. Res. 9 (1984) 803-814
20. Gibson G.E., Park L.C., Zhang H., Sorbi S., and Calingasan N.Y. Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits. Ann. N.Y. Acad. Sci. 893 (1999) 79-94
21. Gibson G.E., Blass J.P., Beal M.F., and Bunik V. The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol. Neurobiol. 31 (2005) 43-63
22. Giguère J.F., and Butterworth R.F. Activities of thiamine-dependent enzymes in two experimental models of thiamine deficiency encephalopathy. Neurochem. Res. 12 (1987) 305-310
23. Huang W., Chen Y., Shohami E., and Weinstock M. Neuroprotective effect of rasagiline, a selective monamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366 (1999) 127-135
24. Huang H.M., Ou H.C., Xu H., Chen H.L., Fowler C., and Gibson G.E. Inhibition of alpha-ketoglutarate dehydrogenase complex promotes cytochrome c release from mitochondria, caspase-3 activation, and necrotic cell death. J. Neurosci. Res. 74 (2003) 309-317
25. Huang H.M., Fowler C., Zhang H., and Gibson G.E. Mitochondrial heterogeneity within and between different cell types. Neurochem. Res. 29 (2004) 651-658
26. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
27. Karuppagounder S.S., Xu H., Pechman D., Chen L.H., DeGiorgio L.A., Gibson G.E., 2008. Translocation of amyloid precursor protein C-terminal fragments to the nucleus precedes neuronal death due to thiamine deficiency-induced mild impairment of oxidative metabolism. Neurochem. Res. Mar 4; [Electronic publication ahead of print].
28. Kragten E., Lalande I., Zimmermann K., Roggo S., Schindler P., Muller D., van Oostrum J., Waldmeier P., and Furst O. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of antiapoptotic compounds CGP3466 and (R)-deprenyl. J. Biol. Chem. 273 (1998) 5821-5828
29. Langlais P.J., and Savage L.M. Thiamine deficiency in rats produces cognitive and memory deficits on spatial tasks that correlate with tissue loss in diencephalons, cortex and white matter. Behav. Brain Res. 68 (1995) 75-89
30. Langlais P.J., Mandel R.J., and Mair R.G. Diencephalic lesions, learning impairments, and intact retrograde memory following acute thiamine deficiency in the rat. Behav. Brain Res. 48 (1992) 177-185
31. Langlais P.J., Zhang S.X., and Savage L.M. Neuropathology of thiamine deficiency: an update on the comparative analysis of human disorders and experimental models. Metab. Brain Dis. 11 (1996) 19-37
32. Magyar K., Palfi M., Tabi T., Kalasz H.B., Szende B., and Szoko1 E. Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem. 11 (2004) 2017-2031
33. Magyar K., Szatmary I., Sezbeni G., and Lengyel J. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. J. Neural Transm. Suppl 72 (2007) 165-173
34. Mair R.G., Otto T.A., Knoth R.L., Rabchenuk S.A., and Langlais P.J. Analysis of aversively conditioned learning and memory in rats recovered from pyrithiamine-induced thiamine deficiency. Behav. Neurosci. 105 (1991) 351-359
35. Mandel S., Weinreb O., Amit T., and Youdim M.B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Rev. 48 (2005) 379-387
36. Mantel N. Ranking procedures for arbitrarily restricted observations. Biometrics 23 (1967) 65-78
37. Maruyama W., Akao Y., Youdim M.B., Davis B.A., and Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78 (2001) 727-735
38. Maruyama W., Youdim M.B., and Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. N.Y. Acad. Sci. 939 (2001) 320-329
39. Maruyama W., Akao Y., Carrillo M., Kitani K., Youdium M.B., and Naoi M. Neuroprotection by propargylamines in Parkinson's disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24 (2002) 675-682
40. Maruyama W., Takahashi T., Youdim M., and Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Trans. 109 (2002) 467-481
41. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Meth. 11 (1984) 47-60
42. Mumby D.G., Cameli L., and Glenn M.J. Impaired allocentric spatial working memory and intact retrograde memory after thalamic damage caused by thiamine deficiency in rats. Behav. Neurosci. 113 (1999) 42-50
43. Mytilineou C., Radcliffe P., Leonaradi E.K., Werner P., and Olanow C.W. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68 (1997) 33-39
44. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. Arch. Neurol. 59 (2002) 1937-1943
45. Parkinson Study Group. A controlled, randomised, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61 (2004) 561-566
46. Pires R.G., Pereira S.R., Oliveira-Silva I.F., Franco G.C., and Ribeiro A.M. Cholinergic parameters and the retrieval of learned and re-learned spatial information: a study using a model of Wernicke-Korsakoff Syndrome. Behav. Brain Res. 162 (2005) 11-21
47. Pitkin S.R., and Savage L.M. Aging potentiates the acute and chronic neurological symptoms of pyrithiamine-induced thiamine deficiency in the rodent. Behav. Brain Res. 119 (2001) 167-177
48. Pitkin S.R., and Savage L.M. Age-related vulnerability to diencephalic amnesia produced by thiamine deficiency: the role of time of insult. Behav. Brain Res. 148 (2004) 93-105
49. Reynolds G.P., Riederer P., Sandler M., Jellinger K., and Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J. Neural Transm. 43 (1978) 271-277
50. Ricaurte G.A., Seiden L.S., and Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303 (1984) 358-364
51. Rindi G., Patrini C., Nauti A., Bellazzi R., and Magni P. Three thiamine analogues differently alter thiamine transport and metabolism in nervous tissue: an in vivo kinetic study using rats. Metab. Brain Dis. 18 (2003) 245-263
52. Semkova I., Wolz P., Schilling M., and Krieglstein J. Selegiline enhances NGF sythesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 315 (1996) 19-30
53. Seniuk N.A., Henderson J.T., Tatton W.G., and Roder J.C. Increased CNTF gene expresion in process-bearing astrocytes following injury is augmented by R(-)deprenyl. J. Neurosci. Res. 37 (1994) 278-286
54. Shibata H. Direct projections from the anterior thalamic nuclei to the retrohippocampal region in the rat. J. Comp. Neurol. 337 (1993) 431-445
55. Speiser Z., Katzir O., Rehavi M., Zabarski T., and Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60 (1998) 387-393
56. Speiser Z., Levy R., and Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J. Neural Transm. [Suppl] 52 (1998) 287-300
57. Speiser Z., Mayk A., Eliash S., and Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J. Neural Transm. 106 (1999) 593-606
58. Speiser A., Mayk A., Litinetsky L., Fine T., Nyska A., Blaugrund E., and Cohen S. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J. Neural Transm. 114 (2007) 595-605
59. Stefanova N., Poewe W., and Wenning G.K. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 210 (2008) 421-427
60. Stocchi F., and Olanow C.W. Neuroprotection in Parkinson's disease: clinical trials. Ann. Neurol. Suppl. 3 (2003) S87-S97
61. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Brenner C., Larochette N., Prévost M.C., Alzari P.M., and Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189 (1999) 381-394
62. Swanson L.W., Kohler C., and Bjorklund A. The limbic region. The septohippocampal system. In: Bjorklund A., Hokfelt T., and Swanson L.W. (Eds). Handbook of Chemical Neuroanatomy, Vol 5, Integrated Systems of the CNS, Pt 1 (1987), Elsevier, Amsterdam 125-277
63. Tatton W.G., Ju W.Y.L., Holland D.P., Tai C., and Kwan M. Deprenyl reduces PC-12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63 (1994) 1572-1575
64. Tatton W., Chalmers-Redman R., and Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 110 (2003) 500-515
65. Tipton K.F., and Youdim M.B.H. The assay of monamine oxidase activity. In: Parvez S., Nagatsu T., Nagatsu I., and Parvez H. (Eds). Methods in Biogenic Amine Research (1983), Elsevier, Amsterdam 141-467
66. Todd K.G., and Butterworth R.F. Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency. J. Neurosci. Res. 52 (1998) 240-248
67. Troncoso J.C., Johnston M.V., Hess K.M., Griffin J.W., and Price D.L. Model of Wernicke's encephalopathy. Arch. Neurol. 38 (1981) 350-354
68. Waldmeier P.C., Boulton A.A., Cools A.R., Kato A.C., and Tatton W.G. Neurorescuing effects of the GADPH ligand CGP 3466B. J. Neural Transm. Suppl. 60 (2000) 197-214
69. Warburton E.C., Baird A., Morgan A., Muir J.L., and Aggleton J.P. The conjoint importance of the hippocampus and anterior thalamic nuclei for allocentric spatial learning: evidence from a disconnection study in the rat. J. Neurosci. 21 (2001) 7323-7330
70. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., and Youdim M.B. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18 (2004) 1471-1473
71. Weinreb O., Amit T., Bar-Am O., Chillag-Talmor O., and Youdim M.B. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann. N. Y. Acad. Sci. 1053 (2005) 348-355
72. Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M.B., and Naoi M. N-propargylamine protects SH-SY5Y cells from apoptosis induced by endogenous neurotoxin N-methylsalsolinol through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural. Transm. 113 (2006) 21-32
73. Yogev-Falach M., Amit T., Bar-Am O., and Youdim M.B. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17 (2003) 2325-2327
74. Youdim M.B., and Weinstock M. Molecular basis on neuroprotective activities of rasagiline and the anti-Alzheimer's drug, TV3326, [(N-propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell. Mol. Neurobiol. 21 (2002) 555-573
75. Youdim M.B., Gross A., and Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase. Br. J. Pharmacol. 132 (2001) 500-506
76. Youdim M.B., Amit T., Falach-Yogev M., Bar-Am O., Maruyama W., and Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activation in the neuroprotective antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem. Pharmacol. 66 (2003) 1635-1641
77. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., and Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79 (2005) 172-179